Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection

Journal of Infectious Diseases

Volumn 211, Issue 2, 2015, Pages 197-205

  Dooley, Kelly E ^a   Denti, Paolo ^c   Martinson, Neil ^a,d   Cohn, Silvia ^a   Mashabela, Fildah ^d   Hoffmann, Jennifer ^a   Haas, David W ^b   Hull, Jennifer ^e   Msandiwa, Regina ^d   Castel, Sandra ^c   Wiesner, Lubbe ^c   Chaisson, Richard E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

efavirenz; HIV tuberculosis co infection; isoniazid preventive therapy; pharmacogenetics; population pharmacokinetics; pregnancy; rifampin

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450 2B6; EFAVIRENZ; GENOMIC DNA; ISONIAZID; RIFAMPICIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ADULT; BEDTIME DOSAGE; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DELIVERY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MIXED INFECTION; PREGNANT WOMAN; PROSPECTIVE STUDY; PUERPERIUM; SOUTH AFRICA; TREATMENT DURATION; TUBERCULOSIS; UMBILICAL CORD BLOOD; VERTICAL TRANSMISSION; VIRUS INHIBITION; VIRUS LOAD; ADOLESCENT; CHEMISTRY; COINFECTION; COMPLICATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; PLASMA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BENZOXAZINES; COHORT STUDIES; COINFECTION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; PLASMA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; SOUTH AFRICA; TUBERCULOSIS; VIRAL LOAD; YOUNG ADULT;

EID: 84922576048     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu429     Document Type: Conference Paper

References (46)

1. Gupta A, Nayak U, Ram M, et al. Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005. Clin Infect Dis 2007; 45:241-9.
2. Khan M, Pillay T, Moodley JM, Connolly CA, Durban Perinatal TB, HIV-1 Study Group. Maternal mortality associated with tuberculosis-HIV-1 co-infection in Durban, South Africa. AIDS 2001; 15:1857-63.
3. Mofenson LM, Laughon BE. Human immunodeficiency virus, Mycobacterium tuberculosis, and pregnancy: a deadly combination. Clin Infect Dis 2007; 45:250-3.
4. Pillay T, Sturm AW, Khan M, et al. Vertical transmission of Mycobacterium tuberculosis in KwaZulu Natal: impact of HIV-1 co-infection. Int J Tuberc Lung Dis 2004; 8:59-69.
5. Pillay T, Khan M, Moodley J, et al. The increasing burden of tuberculosis in pregnant women, newborns and infants under 6 months of age in Durban, KwaZulu-Natal. S Afr Med J 2001; 91:983-7.
6. Bateman C. Much ado over the new South African PMTCT Guidelines. S Afr Med J 2013; 103:218-21.
7. Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care Med 2012; 185:779-84.
8. Nachega J, Coetzee J, Adendorff T, et al. Tuberculosis active casefinding in a mother-To-child HIV transmission prevention programme in Soweto, South Africa. AIDS 2003; 17:1398-400.
9. Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clin Infect Dis 2012; 55:1532-49.
10. Hoffmann CJ, Variava E, Rakgokong M, et al. High prevalence of pulmonary tuberculosis but low sensitivity of symptom screening among HIV-infected pregnant women in South Africa. PLoS One 2013; 8: e62211.
11. Gounder CR, Wada NI, Kensler C, et al. Active tuberculosis casefinding among pregnant women presenting to antenatal clinics in Soweto, South Africa. J Acquir Immune Defic Syndr 2011; 57:e77-84.
12. Kali PB, Gray GE, Violari A, Chaisson RE, McIntyre JA, Martinson NA. Combining PMTCT with active case finding for tuberculosis. J Acquir Immune Defic Syndr 2006; 42:379-81.
13. World Health Organization. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants, 2009. http://www.who.int/hiv/pub/mtct/rappid-Advice-mtct.pdf. Accessed 20 January 2012.
14. Sturt AS, Dokubo EK, Sint TT. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev 2010; CD008440. doi:CD008440.
15. Department of Health of the Republic of South Africa. The South African antiretroviral treatment guidelines, version 14, 2013. http://www.sahivsoc.org/upload/documents/2013%20ART%20Guidelines-Short% 20Combined%20FINAL%20draft%20guidelines%2014%20March% 202013.pdf. Accessed 18 April 2013.
16. Cressey TR, Stek A, Capparelli E, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr 2012; 59:245-52.
17. Bartelink IH, Savic RM, Mwesigwa J, et al. Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda. J Clin Pharmacol 2014; 54:121-32.
18. Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis 2008; 198:948-61.
19. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41:681-90.
20. Luetkemeyer AF, Rosenkranz SL, Lu D, et al. Relationship between weight, efavirenz exposure and virologic suppression in HIV-infected patients on rifampin-based TB treatment in the ACTG A5221 STRIDE study. Clin Infect Dis 2013; 57:586-93.
21. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300:530-9.
22. Manosuthi W, Sungkanuparph S, Tantanathip P, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-Transcriptase inhibitor-based regimens in HIVinfected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009; 48:1752-9.
23. CDC. Managing drug interactions in the treatment of HIV-related tuberculosis, 2013. http://www.cdc.gov/tb/TB-HIV-Drugs/default.htm. Accessed 1 March 2014.
24. Cohen K, Grant A, Dandard C, et al. The effect of rifampicin-based antitubercular therapy and cytochrome P450 2B6 genotype on efavirenz mid-dosing interval concentrations in a South African HIV-infected population. Antiviral Therapy 2009; 14:687-95.
25. Lee L, Soon GH, Chew N, Else L, Amara A, Knoo S. Differential induction of efavirenz metabolism by rifampin without and with isoniazid in healthy volunteers with CYP2B6 516GG and TT genotypes [abstract 516]. In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 3-6 March 2013.
26. Holzinger ER, Grady B, Ritchie MD, et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group Protocols. Pharmacogenet Genom 2012; 22:858-67.
27. Kappelhoff BS, Van Leth F, MacGregor TR, et al. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005; 10:145-55.
28. Beal S, Sheiner L, Boeckmann A, Bauer R. NONMEM users guides (1989-2009). Ellicott City, MD: ICON Development Solutions, 2009.
29. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)-A Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004; 75:85-94.
30. Jonsson EN, Karlsson MO. Xpose-An S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58:51-64.
31. Keizer RJ, Van Benten M, Beijnen JH, Schellens JH, Huitema AD. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed 2011; 101:72-9.
32. Gordi T, Xie R, Huong NV, Huong DX, Karlsson MO, Ashton M. A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br J Clin Pharmacol 2005; 59:189-98.
33. Boffito M, Back DJ, Blaschke TF, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003; 19:825-35.
34. Bradley SE, Ingelfinger FJ, Bradley GP, Curry JJ. The Estimation of Hepatic Blood Flow in Man. J Clin Invest 1945; 24:890-7.
35. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48:303-32.
36. Holford N. The visual predictive check superiority to standard diagnostic (Rorschach) plots [abstract 738]. Presented at: Annual Meeting of the Population Approach Group in Europe, Pamplona, Spain, 2005. http://www.page-meeting.org/?abstract=738. Acccessed 1 March 2014.
37. Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD. Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses. AAPS J 2012; 14:601-11.
38. Loebstein R, Koren G. Clinical relevance of therapeutic drug monitoring during pregnancy. Ther Drug Monit 2002; 24:15-22.
39. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43:1071-87.
40. ENCORE1 Study Group. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naïve adults (ENCORE1): a randomized, double-blind, placebo-controlled, non-inferiority trial. Lancet 2014; 383:1474-82.
41. DiGiacinto JL, Chan-Tack KM, Robertson SM, Reynolds KS, Struble KA. Are literature references sufficient for dose recommendations?. An FDA case study of efavirenz and rifampin. J Clin Pharmacol 2008; 48:518-23.
42. Sustiva labeling update/dosing adjustment with rifampin. Updated 2 March 2012. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm294476.htm. Accessed 18 April 2013.
43. Pedral-Sampaio DB, Alves CR, Netto EM, Brites C, Oliveira AS, Badaro R. Efficacy and safety of efavirenz in HIV patients on rifampin for tuberculosis. Braz J Infect Dis 2004; 8:211-6.
44. Patel A, Patel K, Patel J, Shah N, Patel B, Rani S. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr 2004; 37:1166-9.
45. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697-706.
46. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis. N Engl J Med 2011; 365:1492-501.